(Q39084317)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28082082%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

title

Key European guidelines for the diagnosis and management of patients with phenylketonuria (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28082082%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28082082%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Annet Bosch

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28082082%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Maria Giżewska

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28082082%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Stephan C Huijbregts

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28082082%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

François Maillot

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28082082%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

author name string

Francjan J van Spronsen

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28082082%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Annemiek Mj van Wegberg

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28082082%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Kirsten Ahring

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28082082%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Amaya Bélanger-Quintana

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28082082%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Alberto Burlina

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28082082%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Jaime Campistol

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28082082%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Francois Feillet

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28082082%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Shauna Kearney

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28082082%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Vincenzo Leuzzi

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28082082%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Ania C Muntau

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28082082%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Fritz K Trefz

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28082082%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Margreet van Rijn

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28082082%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

John H Walter

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28082082%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Anita MacDonald

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28082082%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

publication date

10 January 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28082082%20AND%20SRC:MED&resulttype=core&format=json

The Lancet: Diabetes & Endocrinology

9 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28082082%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

volume

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28082082%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

page(s)

743-756

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28082082%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28082082%20AND%20SRC:MED&resulttype=core&format=json

Neonatal screening in Europe; the situation in 2004

9 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

1 reference

7 January 2021

Pathogenesis of cognitive dysfunction in phenylketonuria: review of hypotheses.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Challenges and pitfalls in the management of phenylketonuria

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Suboptimal outcomes in patients with PKU treated early with diet alone: revisiting the evidence

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Dietary management practices in phenylketonuria across European centres

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Management of phenylketonuria in Europe: survey results from 19 countries

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Requirements for a minimum standard of care for phenylketonuria: the patients' perspective

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

The truth of treating patients with phenylketonuria after childhood: the need for a new guideline

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

The broader picture on guideline adherence

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Translating practice guidelines into patient care : guidelines at the bedside

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

A systematic review of evidence for the appropriateness of neonatal screening programmes for inborn errors of metabolism.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Intelligence and quality of dietary treatment in phenylketonuria

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Neurocognitive function in mild hyperphenylalaninemia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Mild hyperphenylalaninemia: to treat or not to treat

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Normal clinical outcome in untreated subjects with mild hyperphenylalaninemia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Estimating the probability of IQ impairment from blood phenylalanine for phenylketonuria patients: a hierarchical meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Termination of dietary treatment in phenylketonuria

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Phenylketonuria in adulthood: a collaborative study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Neurocognitive functioning in adults with phenylketonuria: results of a long term study.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Cognitive, neurophysiological, neurological and psychosocial outcomes in early-treated PKU-patients: a start toward standardized outcome measurement across development.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Progressive neuropsychiatric manifestations of phenylketonuria in adulthood

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Sight-threatening phenylketonuric encephalopathy in a young adult, reversed by diet

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Quality of life in noncompliant adults with phenylketonuria after resumption of the diet

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Assessment of the impact of phenylketonuria and its treatment on quality of life of patients and parents from seven European countries.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Development and psychometric validation of measures to assess the impact of phenylketonuria and its dietary treatment on patients' and parents' quality of life: the phenylketonuria - quality of life (PKU-QOL) questionnaires

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Neuropsychological speed tests and blood phenylalanine levels in patients with phenylketonuria: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

White matter abnormalities in patients with treated hyperphenylalaninaemia: magnetic resonance relaxometry and proton spectroscopy findings.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Diffusion-weighted MR imaging in patients with phenylketonuria: relationship between serum phenylalanine levels and ADC values in cerebral white matter

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Magnetic resonance imaging of the brain in phenylketonuria

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Brain MRI diffusion-weighted imaging in patients with classical phenylketonuria

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Prefrontal cortex cognitive deficits in children treated early and continuously for PKU.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Executive function impairment in early-treated PKU subjects with normal mental development.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

The neuropsychological profile of early and continuously treated phenylketonuria: orienting, vigilance, and maintenance versus manipulation-functions of working memory

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Effects of concurrent phenylalanine levels on sustained attention and calculation speed in patients treated early for phenylketonuria.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Neurocognitive evidence for revision of treatment targets and guidelines for phenylketonuria.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

High phenylalanine levels directly affect mood and sustained attention in adults with phenylketonuria: a randomised, double-blind, placebo-controlled, crossover trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Phenylketonuria: High plasma phenylalanine decreases cerebral protein synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Experimental evidence that phenylalanine is strongly associated to oxidative stress in adolescents and adults with phenylketonuria.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Phenylalanine hydroxylase deficiency: diagnosis and management guideline

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Comparison of tandem mass spectrometry and amino acid analyzer for phenylalanine and tyrosine monitoring--implications for clinical management of patients with hyperphenylalaninemia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Simultaneous determination of phenylalanine and tyrosine in peripheral capillary blood by HPLC with ultraviolet detection

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Blood phenylalanine monitoring for dietary compliance among patients with phenylketonuria: comparison of methods

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Factors affecting the variation in plasma phenylalanine in patients with phenylketonuria on diet

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Stability of blood phenylalanine levels and IQ in children with phenylketonuria

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Variability in phenylalanine control predicts IQ and executive abilities in children with phenylketonuria.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Associations between phenylalanine-to-tyrosine ratios and performance on tests of neuropsychological function in adolescents treated early and continuously for phenylketonuria

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

A preliminary investigation of the role of the phenylalanine:tyrosine ratio in children with early and continuously treated phenylketonuria: toward identification of "safe" levels

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Large daily fluctuations in plasma tyrosine in treated patients with phenylketonuria.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Reassessment of phenylalanine tolerance in adults with phenylketonuria is needed as body mass changes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Long-term treatment with tetrahydrobiopterin in phenylketonuria: treatment strategies and prediction of long-term responders.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Unrestricted consumption of fruits and vegetables in phenylketonuria: no major impact on metabolic control

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Direct and indirect cellular effects of aspartame on the brain.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Neuropsychological and biochemical investigations in heterozygotes for phenylketonuria during ingestion of high dose aspartame (a sweetener containing phenylalanine).

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Artificial sweeteners - a review.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a phase II, multicentre, open-label, screening study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

A Systematic Review of BH4 (Sapropterin) for the Adjuvant Treatment of Phenylketonuria

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Tetrahydrobiopterin responsiveness in phenylketonuria: prediction with the 48-hour loading test and genotype.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Man made disease: clinical manifestations of low phenylalanine levels in an inadequately treated phenylketonuria patient and mouse study.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

The micronutrient status of patients with phenylketonuria on dietary treatment: an ongoing challenge.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Main issues in micronutrient supplementation in phenylketonuria

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Vitamin B12 deficiency in adolescents and young adults with phenylketonuria

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Spastic paraparesis after anaesthesia.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Bone health in phenylketonuria: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

A systematic review of bone mineral density and fractures in phenylketonuria

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Evidence that l-Carnitine and Selenium Supplementation Reduces Oxidative Stress in Phenylketonuric Patients

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Effectiveness of self-management training in type 2 diabetes: a systematic review of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Maternal phenylketonuria and hyperphenylalaninemia. An international survey of the outcome of untreated and treated pregnancies

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Maternal phenylketonuria: report from the United Kingdom Registry 1978-97

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Congenital heart disease in maternal phenylketonuria: report from the Maternal PKU Collaborative Study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Maternal phenylketonuria and hyperphenylalaninemia in pregnancy: pregnancy complications and neonatal sequelae in untreated and treated pregnancies

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Effect of high maternal blood phenylalanine on offspring congenital anomalies and developmental outcome at ages 4 and 6 years: the importance of strict dietary control preconception and throughout pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Phenylketonuria in Children and Mothers: Genes, Environments, Behavior

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Psychosocial issues and outcomes in maternal PKU.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Maternal phenylketonuria: low phenylalaninemia might increase the risk of intra uterine growth retardation

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Maternal mild hyperphenylalaninaemia: an international survey of offspring outcome

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

The international study of pregnancy outcome in women with maternal phenylketonuria: report of a 12-year study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

The Resource Mothers Study of Maternal Phenylketonuria: preliminary findings

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

A practical approach to maternal phenylketonuria management.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Late-treated phenylketonuria mimicking Angelman syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Newborn screening in southeastern Europe

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Adult phenylketonuria outcome and management

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Late-treated phenylketonuria and partial reversibility of intellectual impairment

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Long-term beneficial effects of the phenylalanine-restricted diet in late-diagnosed individuals with phenylketonuria

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Low bone strength is a manifestation of phenylketonuria in mice and is attenuated by a glycomacropeptide diet

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Nutritional management of PKU with glycomacropeptide from cheese whey

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

Living with phenylketonuria: perspectives of patients and their families

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930320-5

7 January 2021

10.1016/S2213-8587(16)30320-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28082082%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

1 reference